Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
Laurent Peyrin‐Biroulet, William J. Sandborn, Remo Panaccione, et al.
Therapeutic Advances in Gastroenterology (2021) Vol. 14
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
Phurpa Wangchuk, Karma Yeshi, Alex Loukas
Trends in Pharmacological Sciences (2024)
Closed Access | Times Cited: 15
Recent advances in bacteria‐based platforms for inflammatory bowel diseases treatment
Jiaoying Lu, Xinyuan Shen, Hongjun Li, et al.
Exploration (2024) Vol. 4, Iss. 5
Open Access | Times Cited: 13
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 919-933
Open Access | Times Cited: 10
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis
Laurent Peyrin‐Biroulet, Peter Bossuyt, Dominik Bettenworth, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 5, pp. 1808-1825
Open Access | Times Cited: 6
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer
Michael Croft, Shahram Salek‐Ardakani, Carl F. Ware
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 12, pp. 939-961
Closed Access | Times Cited: 5
Medical Management of Ulcerative Colitis and Crohn’s Disease—Strategies for Inducing and Maintaining Remission
Mohamed Tausif Siddiqui, Rhytha Kasiraj, Maliha Naseer
Surgical Clinics of North America (2025) Vol. 105, Iss. 2, pp. 435-454
Closed Access
Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
Qian Qiao, Jiachen Sun, Ya Zheng, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea
Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, et al.
Lara D. Veeken (2025)
Closed Access
Blood transcriptomics identifies FEZ1 as a potential biomarker for inflammatory bowel disease
Arman Mokaram Doust Delkhah
Computers in Biology and Medicine (2025) Vol. 187, pp. 109742-109742
Closed Access
Biobetters and biosimilars in Inflammatory Bowel Disease
Jacopo Fanizza, Ilaria Faggiani, Mariangela Allocca, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101992-101992
Closed Access
The use of aptamers as therapeutic inhibitors and biosensors of TNF-alpha
Hossein Samiei Abianeh, Prashant Kesharwani, Amirhossein Sahebkar
International Journal of Biological Macromolecules (2025), pp. 141202-141202
Closed Access
Long-acting injectable nanoparticle formulation for sustained release of anti-TNF-α antibody therapeutic in ulcerative colitis treatment
Yicheng Zhang, Ling Li, Jiayuan Kong, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 1005-1016
Closed Access
pH-responsive CuS/DSF/EL/PVP nanoplatform alleviates inflammatory bowel disease in mice via regulating gut immunity and microbiota
Jinpeng Yao, Yu Chen, Liang Zhang, et al.
Acta Biomaterialia (2024) Vol. 178, pp. 265-286
Closed Access | Times Cited: 4
Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease
Karma Yeshi, Tenzin Jamtsho, Phurpa Wangchuk
Molecules (2024) Vol. 29, Iss. 16, pp. 3954-3954
Open Access | Times Cited: 4
Tumor necrosis factor superfamily signaling: life and death in cancer
Obada Ababneh, Daisuke Nishizaki, Shumei Kato, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 4, pp. 1137-1163
Open Access | Times Cited: 4
Efficacy of biologic and small molecule agents as second‐line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity‐matched cohort study
Gursimran Kochhar, Aakash Desai, Francis A. Farraye, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 3, pp. 297-308
Closed Access | Times Cited: 11
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis
Axel Dignaß, Claire Ainsworth, Susanne Hartz, et al.
Advances in Therapy (2024) Vol. 41, Iss. 12, pp. 4446-4462
Open Access | Times Cited: 3
Caspase‐8 in endothelial cells maintains gut homeostasis and prevents small bowel inflammation in mice
Nathalie Tisch, Carolin Mogler, Ana Stojanovic, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 6
Open Access | Times Cited: 16
Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease
Johannes Stallhofer, Jan Guse, Miriam Kesselmeier, et al.
International Journal of Colorectal Disease (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 9
Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies
María José Aguilar-Castillo, Pablo Cabezudo‐García, Nicolás Lundahl Ciano-Petersen, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 716-716
Open Access | Times Cited: 13
Temporal dynamics of TNF-mediated changes in hematopoietic stem cell function and recovery
A. Nilsson, Isabel Hidalgo, David Bryder, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106341-106341
Open Access | Times Cited: 7
Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial
Iris Dotan, Brian G. Feagan, Virginia Taliadouros, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 8, pp. 1207-1216
Open Access | Times Cited: 7
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY
Noa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 10, pp. 1776-1787
Open Access | Times Cited: 7
The Influence of Aerobic Type Exercise on Active Crohn’s Disease Patients: The Incidence of an Elite Athlete
Konstantinos Papadimitriou
Healthcare (2022) Vol. 10, Iss. 4, pp. 713-713
Open Access | Times Cited: 10
Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis
Noemí Manceñido, Blanca Novella Arribas, Gustavo Mora Navarro, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 3, pp. 421-428
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top